Clinical Trial

Vascular Trial Associated Registry Pilot

Study acronym: VSTAR-P
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-17; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-16
Trial Details
NCT Number NCT07076082
Lead Sponsor Corewell Health West
Collaborators: Henry Ford Hospital
Conditions Peripheral Arterial Disease
Enrollment 350 participants
Start Date 2025-10-15
Primary Completion 2027-10-30 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-16